Truist Financial analyst Joon Lee maintains $Verona Pharma (VRNA.US)$ with a buy rating, and sets the target price at $57.
According to TipRanks data, the analyst has a success rate of 49.7% and a total average return of 23.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Verona Pharma (VRNA.US)$'s main analysts recently are as follows:
Preliminary Q4 sales of $36M indicates that Ohtuvayre is consistently performing well above expectations in its initial quarters. The forecasts for both near-term trajectory and long-term peak sales have been revised upwards, reflecting an optimistic assessment of future financial performance.
Verona Pharma's fourth quarter pre-announcement was described as 'impressive', reflecting an optimistic revenue outlook for Ohtuvayre. Analysts highlight the relative ease of getting patients on Medicare Part B drugs compared to those on Medicare Part D. Additionally, pivotal data indicating that 150 physicians now prescribe Ohtuvayre to over 20 of their patients was noted. This trend is expected to grow as more physicians opt to prescribe this medication during scheduled visits for patients experiencing uncontrolled COPD symptoms.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
儲億銀行分析師Joon Lee維持$維羅納製藥 (VRNA.US)$買入評級，目標價57美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.7%，總平均回報率為23.8%。
此外，綜合報道，$維羅納製藥 (VRNA.US)$近期主要分析師觀點如下：
第四季度初步銷售額爲3,600萬美元，這表明Ohtuvayre在初始季度的表現一直遠高於預期。對短期走勢和長期銷售峯值的預測均已上調，這反映了對未來財務表現的樂觀評估。
維羅納製藥第四季度的預告被描述爲 「令人印象深刻」，這反映了Ohtuvayre樂觀的收入前景。分析人士強調，與醫療保險D部分的患者相比，讓患者服用Medicare b部分藥物相對容易。此外，關鍵數據表明，現在有150名醫生爲20多名患者開了Ohtuvayre處方。隨着越來越多的醫生選擇在慢性阻塞性肺病症狀不受控制的患者定期就診時開這種藥物的處方，這一趨勢預計將增長。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
